Canexia Health

A Global Blueprint for Access to Cancer Testing & Treatment

Delayed diagnosis and treatment have created a crisis for thousands of cancer patients across the world during COVID-19. Countries need to rapidly understand how the pandemic is affecting cancer outcomes while creating equitable access to testing that will last beyond the current crisis.

Project ACTT:

Access To Testing and Treatment

Launched in July 2020, Project ACTT is a federally-funded Canadian program providing circulating tumour DNA (ctDNA) testing as an alternative to surgical tissue biopsy for 2,000 patients with metastatic or recurrent breast, lung, and colorectal cancers. COVID-19 has made it clear ctDNA testing should be considered a first-line alternative to surgical procedures whenever medically indicated.

The Canadian Digital Technology Supercluster approved this initiative in support of a consortium led by Canexia Health to deploy and enhance its minimally-invasive ctDNA test . Partners include AstraZeneca Canada, Queen's University, LifeLabs, Illumina, Eastern Ontario Regional Laboratory, and Genolife.

With the aim of making this life-saving technology available to all Canadians even after the COVID-19 pandemic recedes, Project ACTT is also:

- Generating health economics data to accelerate government health coverage of ctDNA testing
- Enhancing Canexia Health's ctDNA test to cover more solid tumor cancer types
- Localizing testing access by training laboratory staff to conduct testing in-house

For thousands of cancer patients each year, this minimally-invasive blood draw can be performed instead of surgical tissue biopsy to enable oncologists to select treatment options as well as to monitor disease progression.

A Global Blueprint

Using Project ACTT as a blueprint, Canexia Health is now building an ecosystem of partners to replicate the model globally and offset burdens on health systems by ensuring all eligible cancer patients have access to life-saving testing.

Canexia Health's ctDNA test, Follow It®, offered through a growing network of global partners, is commercially available and detects close to 90% of clinically actionable mutations in all cancer types. Further, Canexia Health offers a unique partnership model for local laboratories to set up biomarker testing in-house quickly and effectively. Canexia Health provides its technology and methodology for labs to run testing in-house, while also providing a complete bioinformatics reporting pipeline.

Additional benefits of working with Canexia Health to offer cancer genomic testing in-house include:

- Control of the testing process including staffing, quality control, and reporting
- Quicker time-to-results
- Increased patient privacy and data security
- Significant cost savings vs. average tissue biopsy cost of $1K-$14K depending on cancer type
- Reduced risk and impact to patients of delayed or cancelled tissue biopsy surgeries
- Greater resilience to health systems during future crises

Partner With Us

Partnering with Canexia Health is a cost-effective way to provide quality precision oncology testing and supports efforts to establish and secure reimbursement in localities. This will enable hospitals and laboratories to run ctDNA testing in-house, leading to a sustainable solution regardless of COVID-19 and other health system impacts.

We are seeking to further build our consortium of global pharmaceutical, laboratory, academic, and oncology partners for:

- Sample collection
- Bringing ctDNA testing in-house
- Program funding support
- Health economic studies
- In-country health system expertise

To get involved, contact **bd@canexiahealth.com**

About Canexia Health

Canexia Health makes high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support. Our suite of genomics-based cancer tests is clinically actionable and cost-effective, designed to improve cancer treatment and monitoring.
With our extensive scientific experience, specialized genomics-based tests, and support from pharmaceutical and diagnostic partners, we are leading the shift towards precision oncology.

1 ctDNA testing has been shown to be useful in the detection of disease recurrence and resistance mutations as evidenced by reimbursement of such testing in the US for certain cancers. If an actionable cancer mutation is discovered by a ctDNA test, an oncologist can immediately recommend a targeted therapy. If no actionable mutation is found, the patient's oncologist can then determine if a tissue biopsy or therapy is required. Because ctDNA testing requires only a simple blood draw, it is an easily accessible method for cancer treatment selection and monitoring.